Shares of Becton, Dickinson BDX moved higher by 0.0% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 71.70% over the past year to $4.55, which beat the estimate of $3.11.
Revenue of $5,315,000,000 higher by 25.80% from the same period last year, which beat the estimate of $4,880,000,000.
Guidance
The upcoming fiscal year's EPS expected to be between $12.75 and $12.85.
The upcoming fiscal year's revenue expected to be between $19,171,000,000 and $19,513,000,000.
Details Of The Call
Date: Feb 04, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/isdudxg2
Price Action
Company's 52-week high was at $286.72
Company's 52-week low was at $197.75
Price action over last quarter: Up 10.22%
Company Description
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.